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Several evidence have been reported about dietary 
types on cognitive outcomes. Among them, there were 
some well-known types with beneficial effects. They in-
clude Dietary Approaches to Stop Hypertension (DASH), 
Mediterranean diet, Mediterranean-DASH Intervention 
for Neurodegenerative Delay (MIND) [5], Low carbohy-
drate diet (LCD) [6]. In the light of LCD, the authors and 
colleagues have reported clinical studies for LCD so far. 
We have developed three meal types of LCD, which are 
super-, standard- and petite-LCD [6]. These LCD have 
been widely prevalent through the activity of Japan LCD 
promotion association (JLCDPA) [6]. 
There have been several factors involving patho-
physiological cause for Type 2 Diabetes Mellitus (T2DM) 
and Alzheimer’s Disease (AD). The presence of inflam-
mation, defective insulin signaling, and mitochondrial 
dysfunction has been associated with obesity and the 
enhancement of stress signals [7]. Similarly, chronic 
inflammation in the brain has been supposed to con-
tribute the development of the pathology of AD. Conse-
quently, both of these could be suggested to be one of 
the risks of common molecular pathology [8]. 
Certain correlation was reported between glucose 
metabolism and AD. For the patients with established 
AD, the cognitive impairment has been correlated re-
markably with the reduced level of glucose uptake [9]. 
Furthermore, various changes in energy metabolism of 
the brain has been found in the development for AD 
[10].
Diabetes has been one of the main risk factors for 
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Introduction
One of the recent crucial medical problems in the 
world has been diabetes mellitus, which is increasing in 
developed and also developing countries [1]. Further-
more, dementia and Mild Cognitive Impairment (MCI) 
in the elderly has been also medical and social prob-
lems due to the extended life span. The both diseases 
are interrelated and there are many influencing factors 
on them [2]. These topics are involved and described in 
this article.
Concerning dementia and MCI, dietary intervention 
has been an important approach for long worldwide. 
For several nutrients related to cognitive function, ma-
jor dietary sources have been found, such as B vitamins 
(B6, B12, folate), antioxidants (Vit C, E, carotenes, flavo-
noids) and Vit D [3]. In addition, macronutrients include 
carbohydrates, proteins, dietary fat, saturated fatty ac-
ids (FA), polyunsaturated FA (PUFA), monounsaturated 
FA (MUFA), and so on [4].
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dementia. There were studies concerning glycemic 
control and the onset of dementia. Among these, AC-
CORD-MIND (Action to Control Cardiovascular Risk in 
Diabetes Memory in Diabetes Study) has been known. 
As a result, no significant difference was found in the 
effect on cognitive function in the intensive treatment 
group (goal with A1 c < 6.0%) compared to the standard 
treatment group (goal with A1 c 7.0-7.9%) [11]. Similar 
results were observed with other reports [12]. There 
are few large-scale Randomized Controlled Trials (RCTs) 
of diabetes management including cognitive function as 
an endpoint. Consequently, it has been not clear wheth-
er strict management is effective for preventing the on-
set of dementia [1].
As for the relationship between glycemic control and 
dementia, the risk for developing dementia has been 
higher in the cases with severe hypoglycemic seizures. 
Conversely, the risk of severe hypoglycemic seizures has 
been higher in the cases with dementia [13]. Thus, both 
factors may interact each other to cause a vicious cycle. 
Consequently, prevention of hypoglycemia and stable 
glucose variability have been important according to 
the guideline of diabetic management [14]. 
There was a study for the patients with MCI or de-
mentia due to AD, in which anti-diabetic agent met-
formin was provided [15]. As a result, metformin 
seemed to show improved executive function, associat-
ed with probable improvement of function for learning, 
memory and attention. 
A study of a systematic review and meta-analysis 
was reported for the relationship between obesity and 
dementia [16]. From 1612 abstracts and 21 completely 
met the criteria, the result was that obesity with < 65 
years showed a positive association on dementia with 
Risk Ratio (RR) 1.41. In contrast, the opposite result was 
found in those aged 65 and over as RR 0.83 [16]. Thus, 
the relationship between obesity and dementia varies 
with age. 
There are various controversies concerning the re-
lationship between Total Cholesterol (TC) value and 
increased risk of AD. Meta-analyses were conducted 
including 17 studies, 23,338 participants for 20 years 
[17]. The evaluation would vary by each study. For mid-
dle-aged studies, the results showed significant cor-
relations. In contrast, studies for older subjects tended 
to show less significant correlations. Consequently, it 
seemed to be depending on the age of the subjects [17]. 
In general, cases of high TC in middle age may increase 
the risk of AD in later life or may increase the onset of 
AD pathology. Furthermore, there are many reports 
that HDL-C and triglyceride levels in the elderly are not 
related to the elevated risk of dementia [17]. 
Can administration of statins for the patients with 
dyslipidemia suppress the onset of dementia? Cochrane 
review analyzed two large-scale RCTs in high-risk pa-
tients (n = 26,340) with vascular disease [18]. As a re-
sult, statin administration in the elderly could not pre-
vent the onset of dementia and the decline in cognitive 
function.
With regard to the blood pressure, age-related hypo-
tension is significantly associated with dementia and AD 
onset. In the patients with dementia and MCI on the An-
tihypertensive Drugs (AHDs), cognitive function declines 
when daytime blood pressure has been lower. Further-
more, the progress for decreased cognitive function has 
been reported to be significantly faster [19]. Thus, ex-
cessive depression may reduce cognitive function. 
In previous studies such as traditional Systematic Re-
view (SR) and Meta-Analysis (MA), high physical activi-
ty has been shown to reduce the risk of dementia and 
cognitive decline [20]. In contrast, there has been an 
opposite report. The Cochrane Review concludes that 
the analysis of MA does not clearly show the evidence 
for its effectiveness on cognitive function in the patients 
with dementia [21]. 
There is a large RCT for aged patients with demen-
tia. It has been Finnish Geriatric Intervention Study to 
Prevent Cognitive Impairment and Disability (FINGER). 
Among them, modifiable vascular and lifestyle-related 
risk factors have been analyzed [22]. As a result, it has 
supposed that multi-domain intervention would relieve 
or maintain the cognitive function in elderly people with 
risk for dementia.
In summary, various health and medical problems 
including diabetes, dementia and MCI have been dis-
cussed. There are not simple and effective way to solve 
these complex problems. With multi-factorial analyses 
and integrative approach, multi-domain interventions 
would become the recommended treatments for clin-
ical practice and research in the future.
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